clinical setting to determine whether or not a particular cancer patient is a candidate for such treatment with regards to the p53 status of the tumor. Once identified and characterized, novel NOS2 inhibitors may be administered to candidate cancer patients and evaluated in their ability to treat various tumors.

The described methods are the subject of U.S. provisional patent application, USSN 60/109,563, filed on November 23, 1998 by the Public Health Service on behalf of the Federal Government. Furthermore, the initial report and characterization of the invention is described in: Ambs *et al,* Nature Medicine (1998) vol. 4, no.12:1371–1376.

References

1. Nguyen *et al* (1992) PNAS 89:3030–3034.
2. Jenkins *et al* (1995) PNAS 92:4392–4396.
3. Thomsen *et al* (1995) Br. J. Cancer 72:41–44.
4. Ellie *et al* (1995) Neuroreport 7:294–296.
5. Ambs *et al* (1998) Cancer Res. 58:334–341.
6. Gallo *et al* (1998) J. Natl. Cancer Inst. 90:587–596.
7. Messmer *et al* (1996) Biochem J. 319:299–305.
8. Forrester, K. *et al* (1996) PNAS 93:2442–2447.
9. Calmels *et al* (1997) Cancer Res. 57:3365–3369.
10. Ambs *et al* (1997) Faseb J. 11:443–448.
11. Ambs *et al* (1998) PNAS 95:8823–8828.
12. Thomsen *et al* (1997) Cancer Res. 57:3300–3304.

Under the present proposal, the overall goal of the CRADA collaboration will involve the following:

1. Use of the genetically engineered cells lines and assays in preclinical screening assays of potential NOS2 inhibitors; and

2. Use of the cell lines and candidate NOS2 inhibitors in diagnostic, preclinical and clinical settings.

Party Contributiions:

The role of the NCI in the CRADA may include, but not be limited to:

1. Providing intellectual, scientific, and technical expertise and experience to the research project.

2. Providing the CRADA Collaborator with information and data relating to the methods developed to assess the activity of p53 and NOS2 and to screen for potential modulators of NOS2 activity.

3. Planning research studies and interpreting research results.

4. Carrying out research to validate the use of the NOS2-related methods and candidate NOS2 inhibitors in preclinical, diagnostic and clinical settings.

5. Publishing research results.

6. Developing additional potential applications of the methods.

The role of the CRADA Collaborator may include, but not be limited to:

1. Providing significant intellectual, scientific, and technical expertise or experience to the research project.

2. Planning research studies and interpreting research results.

3. Producing candidate NOS2 inhibitors under cGMP conditions in sufficient quantities to support the CRADA studies.

4. Carrying out research to validate the use of the NOS2-related methods and candidate NOS2 inhibitors in preclinical, diagnositc and clinical settings, including toxicologic and pharmacologic assays, as appropriate.

5. Providing technical and/or financial support to facilitate scientific goals and for futher design of applications of the technology outlined in the agreement.

6. Publishing research results.

Selection criteria for choosing the CRADA Collaborator may include, but not be limited to:

1. A demonstrated record of success in the screening of chemotherapeutic agents.

2. A demonstrated background and expertise in cancer research and treatment.

3. The ability to collaborate with NCI on further research and development of this technology. This ability will be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development.

4. The demonstration of adequate resources to perform the research and development of this technology (*e.g.* facilities, personnel and expertise) and to accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

5. The willingness to commit best effort and demonstrated resources to the research and development of this technology, as outlined in the CRADA Collaborator's proposal.

6. The demonstration of expertise in the commercial development and production of products related to this area of technology.

7. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities.

8. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.

9. The agreement to be bound by the appropriate DHHS regulations relating to human subjects and to all PHS policies relating to the use and care of laboratory animals.

10. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the distribution of future patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor.

Dated: October 8, 1999.

Kathleen Sybert,

Chief, Technology Development and Commercialization Branch, National Cancer Institute, National Institutes of Health.

[FR Doc. 99–32138 Filed 12–10–99; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice if hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel ZRG1 BM–1 01.

Date: December 7, 1999.

Time: 2:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Timothy J. Henry, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4180, MSC 7808, Bethesda, MD 20892, (301) 435–1147.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: December 10, 1999.

Time: 11:30 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: David M. Monsees, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3199, MSC 7770, Bethesda, MD 20892, (301) 435–0684, monseesd@drg.nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: December 16, 1999.

Time: 2:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Jay Cinque, MSC, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, MSC 7846, Bethesda, MD 20892, (301) 435–1252.

This notice is being published less than 15 days prior to the meeting due the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: December 16, 1999.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Marcelina B. Powers, DVM, MS, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7804, Bethesda, MD 20892, (301) 435–1720.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: December 20, 1999.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Marcelina B. Powers, DVM, MS, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7804, Bethesda, Md. 20892, (301) 435–1720.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: December 21, 1999.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telepone Conference Call).

Contact Person: Marcelina B. Powers, DVM, MS, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7804, Bethesda, MD 20892, (301) 435–1720.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: December 6, 1999.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 99–32137 Filed 12–10–99; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Changes to a Fiscal Year (FY) 1999 Funding Opportunities Notice

AGENCY: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Modification/Clarification of a Notice of Funding Availability Regarding the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment (CSAT) Community Treatment Program Funding Announcement.

SUMMARY: This notice is to inform the public that certain requirements/statements in the SAMHSA/CSAT Program Announcement 99–050 entitled, Comprehensive Community Treatment Program for the Development of New and Useful Knowledge (Short Title: Community Treatment Program), published in the **Federal Register** on March 8, 1999 (Volume 64, Number 44, pages 11027–11031) have been modified/clarified. It is, therefore, critical that potential applicants for the May 10, 2000 and future receipt dates for applications obtain a copy of the Addendum that contains the modified/clarified Purpose and Rationale, Eligibility, Availability of Funds, Period of Support and Program Description and Project Requirements sections for the Community Treatment Program announcement (PA 99–050) before preparing and/or submitting an application.

The full Program Announcement and the addendum that includes modified/clarified sections are available via the SAMHSA web site—www.samhsa.gov, or from the National Clearinghouse for Alcohol and Drug Information (Telephone: 800–729–6686).

Additional information about the modifications/clarifications and/or programmatic assistance may be obtained from: Thomas Edwards, Jr., Division of Practice and Systems Development, Center for Substance Abuse Treatment, SAMHSA, Rockwall II, Suite 740, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (301) 443–8453.

Dated: December 6, 1999.

Richard Kopanda,

Executive Office, Substance Abuse and Mental Health Services Administration.

Addendum to PA 99–050

December 1999

ADDENDUM to SAMHSA/CSAT Program Announcement PA 99–050, Comprehensive Community Treatment Program for the Development of New and Useful Knowledge

The following changes to the appended PA 99–050 modify/clarify the Purpose and Rationale, Eligibility, Availability of Funds, Period of Support, and Program Description and Project Requirements sections. It is important to note that potential applicants for the May 10, 2000 and future receipt dates must take the following modifications/clarifications into consideration before preparing and/or submitting an application.

Purpose and Rationale

(Replace the existing second sentence of the third paragraph with the following.)

Through this Program Announcement (PA), CSAT will support two types of grants: (1) Full studies of treatment programs and services, and (2) exploratory/pilot studies.

Note: CSAT will no longer support enhancement/expansion grants under this PA; therefore, all references to enhancement/expansion grants throughout the PA should be ignored.

Eligibility

(The second paragraph of the Eligibility section has been deleted.)